197792-60-2

Basic information

• Product Name: METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE
• Synonyms: METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE;tert-butyl 2-(3-(aMinoMethyl)phenyl)acetate;Methyl [3-(aminomethyl)phenyl]acetate hydrochloride (1:1);METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HCL
• CAS NO: 197792-60-2
• Molecular Formula: C₁₀H₁₃NO₂*ClH
• Molecular Weight: 215.68
• Mol File: 197792-60-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE(197792-60-2)
• EPA Substance Registry System: METHYL 2-(3-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE(197792-60-2)

Safety Data

• Hazardous Substances Data: 197792-60-2(Hazardous Substances Data)

Upstream product

• 52798-00-2 (3-cyano-phenyl)-acetic acid methyl ester 

Downstream Products

• 930785-13-0 2-butoxy-8-methoxy-9-{6-[4-(3-methoxycarbonylmethylbenzyl)aminobutoxy]pyridin-3-ylmethyl}adenine 
• 223490-73-1 (3-(((2-(3-chloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenyl)-acetic acid methyl ester 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.